FilingsTodayAbbVie
At a glance
AbbVie reported 2025 revenue of $61.16B, up 8.6% from $56.33B in 2024. Over 4 years since 2021 ($56.2B), that is growth of about 2.1% a year. Operating margin was 24.6%, down from 31.9% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 3 insiders reported 0 open-market purchases and 4 sales ($18.9M). 2 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $8.2M by EVP, CHIEF BUS/STRAT OFFICER Nicholas Donoghoe on Aug 18, 2026.
AbbVie filed 17 current reports (Form 8-K) in the last 12 months, most often for results of operations (9), other events (4), regulation fd disclosure (2) and officer or director change (1). The latest officer or director change was reported on Oct 15, 2026.
2 of the 20 investors tracked here held AbbVie at the last quarter end, worth $1.01B combined. It is the largest weight for National Pension Service (Korea) (0.7% of its portfolio), followed by Bridgewater Associates (0%). Added: National Pension Service (Korea). Reduced: Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $11.54B | $11.84B | $4.86B | $4.28B | $4.23B |
| Diluted EPS | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Dividend per share | $5.31 | $5.71 | $5.99 | $6.29 | $6.65 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined